|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Irritable Bowel Syndrome | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Colonic Diseases | |||||
| Colonic Diseases, Functional | |||||
| Digestive System Diseases | |||||
| Disease | |||||
| Gastrointestinal Diseases | |||||
| Intestinal Diseases | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| alosetron | |||||
| 5 | More general drug interventions related to this trial | ||||
| Gastrointestinal Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Serotonin Agents | |||||
| Serotonin Antagonists | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| GlaxoSmithKline | |||||